临床药物遗传学实施联盟 HLA-B 基因型和阿巴卡韦剂量指南。
Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.
机构信息
Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA.
出版信息
Clin Pharmacol Ther. 2012 Apr;91(4):734-8. doi: 10.1038/clpt.2011.355. Epub 2012 Feb 29.
Abstract
Human leukocyte antigen B (HLA-B) is responsible for presenting peptides to immune cells and plays a critical role in normal immune recognition of pathogens. A variant allele, HLA-B*57:01, is associated with increased risk of a hypersensitivity reaction to the anti-HIV drug abacavir. In the absence of genetic prescreening, hypersensitivity affects ~6% of patients and can be life-threatening with repeated dosing. We provide recommendations (updated periodically at http://www.pharmkgb.org) for the use of abacavir based on HLA-B genotype.
摘要
人类白细胞抗原 B（HLA-B）负责向免疫细胞呈递肽，在正常的病原体免疫识别中发挥关键作用。一个变异等位基因 HLA-B*57:01 与对 HIV 药物阿巴卡韦产生过敏反应的风险增加有关。在没有遗传预筛选的情况下，过敏反应影响约 6%的患者，并且随着重复给药可能会危及生命。我们根据 HLA-B 基因型提供了使用阿巴卡韦的建议（定期在 http://www.pharmkgb.org 更新）。
相似文献
1
Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.临床药物遗传学实施联盟 HLA-B 基因型和阿巴卡韦剂量指南。
Clin Pharmacol Ther. 2012 Apr;91(4):734-8. doi: 10.1038/clpt.2011.355. Epub 2012 Feb 29.
2
Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update.临床药物遗传学实施联盟 HLA-B 基因型和阿巴卡韦剂量指南：2014 年更新。
Clin Pharmacol Ther. 2014 May;95(5):499-500. doi: 10.1038/clpt.2014.38. Epub 2014 Feb 21.
3
Abacavir pharmacogenetics--from initial reports to standard of care.阿巴卡韦药物遗传学——从最初的报告到标准治疗。
Pharmacotherapy. 2013 Jul;33(7):765-75. doi: 10.1002/phar.1278. Epub 2013 May 3.
4
Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing.临床药物遗传学实施联盟指南：HLA-B 基因型与卡马西平剂量。
Clin Pharmacol Ther. 2013 Sep;94(3):324-8. doi: 10.1038/clpt.2013.103. Epub 2013 May 21.
5
Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.临床药物基因组学实施联盟关于CYP2C9和HLA - B基因型与苯妥英钠给药的指南。
Clin Pharmacol Ther. 2014 Nov;96(5):542-8. doi: 10.1038/clpt.2014.159. Epub 2014 Aug 6.
6
Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine.关于阿巴卡韦诱导的过敏反应研究：药物遗传学向个体化医学转化的成功范例。
Sci China Life Sci. 2013 Feb;56(2):119-24. doi: 10.1007/s11427-013-4438-8. Epub 2013 Feb 8.
7
Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity.HLA B*5701基因分型在预防阿巴卡韦超敏反应中的成本效益分析。
Pharmacogenetics. 2004 Jun;14(6):335-42. doi: 10.1097/00008571-200406000-00002.
8
A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase.一种基于HIV逆转录酶序列变异来降低与B*5701相关的阿巴卡韦超敏反应的简单筛查方法。
Clin Infect Dis. 2007 Jun 1;44(11):1503-8. doi: 10.1086/517499. Epub 2007 Apr 18.
9
Abacavir adverse reactions related with HLA-B*57: 01 haplotype in a large cohort of patients infected with HIV.在一大群感染艾滋病毒的患者中，阿巴卡韦不良反应与HLA - B*57:01单倍型的相关性。
Pharmacogenet Genomics. 2020 Oct;30(8):167-174. doi: 10.1097/FPC.0000000000000409.
10
HLA-B*5701 screening for hypersensitivity to abacavir.进行HLA-B*5701筛查以检测对阿巴卡韦的超敏反应。
N Engl J Med. 2008 Feb 7;358(6):568-79. doi: 10.1056/NEJMoa0706135.
引用本文的文献
1
Gaps in guideline adherence: evaluating HLA-B*57:01 screening for abacavir sensitivity and the implementation of evidence-based HIV care.指南依从性的差距：评估HLA-B*57:01筛查对阿巴卡韦敏感性及循证HIV治疗的实施情况
Clin Biochem. 2025 Aug 18;139:110992. doi: 10.1016/j.clinbiochem.2025.110992.
2
The history and future of pharmacogenetics in Aotearoa/New Zealand.新西兰的药物遗传学历史与未来。
J R Soc N Z. 2024 Oct 6;55(6):2422-2439. doi: 10.1080/03036758.2024.2406824. eCollection 2025.
3
Pharmacogenetics of the Treatment of Neglected Diseases.被忽视疾病治疗的药物遗传学
Genes (Basel). 2025 Jan 5;16(1):54. doi: 10.3390/genes16010054.
4
Pharmacogenomic profiling of the South Korean population: Insights and implications for personalized medicine.韩国人群的药物基因组学分析：对个性化医疗的见解与启示。
Front Pharmacol. 2024 Dec 3;15:1476765. doi: 10.3389/fphar.2024.1476765. eCollection 2024.
5
[Pharmaceutical Indication Service in a case of palmar-plantar erythema after amoxicillin and ibuprofen treatment].[阿莫西林和布洛芬治疗后掌跖红斑病例的药物适应症服务]
Farm Comunitarios. 2024 Sep 19;16(4):83-87. doi: 10.33620/FC.2173-9218.(2024).22. eCollection 2024 Oct 15.
6
[Selection of pharmacogenomic variants and methodology for their use in community pharmacy].[药物基因组学变异的选择及其在社区药房中的应用方法]
Farm Comunitarios. 2024 Sep 17;16(4):61-82. doi: 10.33620/FC.2173-9218.(2024).27. eCollection 2024 Oct 15.
7
Severe cutaneous adverse reactions.严重皮肤不良反应。
Nat Rev Dis Primers. 2024 Apr 25;10(1):30. doi: 10.1038/s41572-024-00514-0.
8
AI can help to tailor drugs for Africa - but Africans should lead the way.人工智能有助于为非洲量身定制药物——但非洲人应引领这一进程。
Nature. 2024 Apr;628(8007):265-267. doi: 10.1038/d41586-024-01001-y.
9
Implementation of Pharmacogenetics in First-Line Care: Evaluation of Its Use by General Practitioners.一线医疗中实施药物遗传学：全科医生对其应用的评估。
Genes (Basel). 2023 Sep 22;14(10):1841. doi: 10.3390/genes14101841.
10
Use of the Electronic Health Record for Monitoring Adverse Drug Reactions.电子健康记录在监测药物不良反应中的应用。
Curr Allergy Asthma Rep. 2023 Jul;23(7):417-426. doi: 10.1007/s11882-023-01087-w. Epub 2023 May 16.
本文引用的文献
1
Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era.高效抗逆转录病毒治疗时代阿巴卡韦的使用与急性心肌梗死和脑血管事件风险。
Clin Infect Dis. 2011 Jul 1;53(1):84-91. doi: 10.1093/cid/cir269.
2
Delayed drug hypersensitivity: models of T-cell stimulation.迟发性药物过敏反应：T 细胞刺激模型。
Br J Clin Pharmacol. 2011 May;71(5):701-7. doi: 10.1111/j.1365-2125.2010.03764.x.
3
Pharmacogenetics: from bench to byte--an update of guidelines.药物遗传学：从实验室到字节——指南更新。
Clin Pharmacol Ther. 2011 May;89(5):662-73. doi: 10.1038/clpt.2011.34. Epub 2011 Mar 16.
4
Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics.基于药物基因组学的处方实用建议：2010 年 ESF-UB 药物遗传学和药物基因组学会议。
Pharmacogenomics. 2011 Jan;12(1):113-24. doi: 10.2217/pgs.10.147.
5
Pharmacogenetics of drug hypersensitivity.药物过敏的药物遗传学。
Pharmacogenomics. 2010 Jul;11(7):973-87. doi: 10.2217/pgs.10.77.
6
Host determinants of HIV-1 control in African Americans.非洲裔美国人中 HIV-1 控制的宿主决定因素。
J Infect Dis. 2010 Apr 15;201(8):1141-9. doi: 10.1086/651382.
7
Genetics and genomics of ankylosing spondylitis.强直性脊柱炎的遗传学和基因组学。
Immunol Rev. 2010 Jan;233(1):162-80. doi: 10.1111/j.0105-2896.2009.00852.x.
8
Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.阿巴卡韦-拉米夫定与替诺福韦-恩曲他滨用于初治HIV-1感染的治疗比较
N Engl J Med. 2009 Dec 3;361(23):2230-40. doi: 10.1056/NEJMoa0906768. Epub 2009 Dec 1.
9
Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America.美国传染病学会艾滋病医学协会《2009年更新：人类免疫缺陷病毒感染者管理的初级保健指南》
Clin Infect Dis. 2009 Sep 1;49(5):651-81. doi: 10.1086/605292.
10
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin.HLA - B*5701基因型是氟氯西林所致药物性肝损伤的主要决定因素。
Nat Genet. 2009 Jul;41(7):816-9. doi: 10.1038/ng.379. Epub 2009 May 31.
Zotero 插件